| 1 |
Global Strategy for Asthma Management and Prevention-Global Initiativefor Asthma-GINA.2018[EB/OL]．(2018-03-05)[2018-12-10]．EB/OL]．[2018/12/20]．https：//ginasthma. org/2018- gina-report-global-strategy-for-asthma-management- and-prevention/.
URL
|
| 2 |
王 彦，吴 奎，王长征，等. 支气管哮喘患者的高分辨率CT的常见表现[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(6): 772-775.
|
| 3 |
娄月妍，郑 宇，张丽妍，等. 呼出气一氧化氮在哮喘中的临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(3): 297-301.
|
| 4 |
Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. The Lancet, 2019, 394(10196): 407-418.
|
| 5 |
Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact[J]. Asthma Research and Practice, 2017, 3(1): doi: 10.1186/s40733-016-0029-3. |
| 6 |
Custovic A, Johnston SL, Pavord I, et al. EAACI position statement on asthma exacerbations and severe asthma[J]. Allergy, 2013, 68(12): 1520-1531.
|
| 7 |
Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX)[J]. Respir Med, 2006，100(3): 434-450.
|
| 8 |
Coyle AJ, Ackerman SJ, Burch R, et al. Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation[J]. J Clin Invest, 1995, 95(4): 1735-1740.
|
| 9 |
Katz LE, Gleich GJ, Hartley BF, et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma[J]. Ann Am Thorac Soc, 2014, 11(4): 531-536.
|
| 10 |
Zeiger RS, Schatz M, Dalal AA, et al. Blood eosinophil count and outcomes in severe uncontrolled asthma: A prospective study[J]. J Allergy Clin Immunol Pract, 2017, 5(1): 144-153.
|
| 11 |
Wang F, Liu T, Lan Z, et al. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A Systematic Review and Meta-Analysis[J]. PLOS ONE, 2016, 11(11): e166833.
|
| 12 |
Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy[J]. Int Immunol, 2009, 21(12): 1303-1309.
|
| 13 |
Maselli DJ, Rogers L, Peters JI. Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use[J]. 2018, 14: 2059-2068.
|
| 14 |
Catley MC. Asthma & COPD-IQPC′s Second Conference[J]. IDrugs，2010, 13(9): 601-604.
|
| 15 |
Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity[J]. Human Antibodies, 2009, 18(1-2): 17-27.
|
| 16 |
Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics，and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of subjects with mild asthma[J]. J Allergy Clin Immunol, 2010, 125(6): 1237-1244.
|
| 17 |
张建忠. 2017年11月FDA批准新药概况[J]. 上海医药，39(3): 83.
|
| 18 |
Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions：version5.1.0[EB/OL]. (2011-03)[2018-12-10]. EB/OL]．[2018/12/10]. https：//www.cochrane.org/handbook.
URL
|
| 19 |
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial[J]. The Lancet, 2016, 388(10056): 2128-2141.
|
| 20 |
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial[J]. The Lancet, 2016，388(10056):2115-2127.
|
| 21 |
Park H, Kim M, Imai N, et al. A Phase 2a Study of benralizumab for patients with eosinophilic asthma in south korea and Japan[J]. Int Arch Allergy Immunol, 2016, 169(3): 135-145.
|
| 22 |
Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Respi Med, 2017, 5(7): 568-576.
|
| 23 |
Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study[J]. Lancet Respi Med, 2014, 2(11): 879-890.
|
| 24 |
Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma[J]. N Engl J Med, 2017, 376(25): 2448-2458.
|
| 25 |
Tan L, Gódor D, Bratt J, et al. Benralizumab: a unique IL-5 inhibitor for severe asthma[J]. J Asthma Allergy, 2016, 10: 71-81.
|
| 26 |
Chlumsky J, Striz I, Terl M, et al. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma[J]. J Int Med Res, 2006, 34(2): 129-139.
|
| 27 |
Ghazi A, Trikha A, Calhoun WJ. Benralizumab-a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity-a novel approach for the treatment of asthma[J]. Expert Opin Biol Therapy, 2011, 12(1): 113-118.
|
| 28 |
Khorasanizadeh M, Eskian M, Assa′Ad AH, et al. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα，in Uncontrolled Eosinophilic Asthma[J]. Int Rev Immunol, 2016, 35(4): 294-311.
|
| 29 |
Menzella F, Lusuardi M, Galeone C, et al. The clinical profile of benralizumab in the management of severe eosinophilic asthma[Z]. London, England: SAGE Publications, 2016: 10, 534-548.
|
| 30 |
Markham A. Benralizumab: First Global approval[J]. Drugs, 2018，78(4): 505-511.
|